United States Patent 11,254,649: Hemifumarate Salt Claims, Scope, and Landscape
US Patent 11,254,649 is a salt-and-use patent built around a single defined active ingredient: the hemifumarate salt of (S)[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]-methanone, including specified amorphous and crystalline forms. The claim set then expands into (i) a pharmaceutical composition and (ii) cancer treatment methods across a defined list of solid and hematologic cancers, with a specific subset anchored to BRAF V600 mutant melanoma and an explicit combination with vemurafenib.
What is claimed, in one line?
A specific hemifumarate salt (amorphous or crystalline), alone or in a composition with excipients, for treating selected cancers, including a dedicated method for BRAF V600 mutant melanoma in combination with vemurafenib.
Claim 1: What is the core product scope?
Claim 1 is the anchor independent claim for product definition.
- Type: compound claim
- Salt form: hemifumarate
- Active: (S)[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]-methanone
- Stereochemistry: explicitly (S)
- Physical form: not limited in Claim 1 (physical form becomes explicit in dependent claims)
Practical scope implication
- Any commercial or investigational equivalent that is a hemifumarate of that exact (S)-configured API is within the claim’s product boundary.
- Variations in polymorph or amorphous/crystalline state are handled by dependent claims rather than Claim 1 itself.
Claims 2–3: How does the patent fence off polymorph and morphology?
- Claim 2: hemifumarate salt of Claim 1 is amorphous
- Claim 3: hemifumarate salt of Claim 1 is crystalline
Practical scope implication
- The patent is structured so that enforcement is not dependent on proving a single solid-state form:
- If an infringer ships an amorphous product, Claim 2 can be asserted.
- If it ships a crystalline form, Claim 3 can be asserted.
- Claim 1 remains a broader “hemifumarate salt” backstop.
Competitive design-around reality
- A party wanting to avoid this patent’s product claims cannot typically escape by switching amorphous vs crystalline; both are explicitly claimed.
Claim 4: What does the composition claim add?
Claim 4 claims a pharmaceutical composition comprising:
- the hemifumarate salt of Claim 1
- plus a pharmaceutically acceptable excipient
Practical scope implication
- This is a standard composition claim but materially important:
- It covers formulation activities (mixing) and commercial product dosage forms built on the claimed salt.
- It does not require any dosing regimen in Claim 4; dosing is addressed later in the method claims.
Claims 5–6: Does the composition claim also lock in morphology?
- Claim 5: composition where the hemifumarate salt is amorphous
- Claim 6: composition where the hemifumarate salt is crystalline
Practical scope implication
- The formulation layer is reinforced with solid-state specificity.
- This reduces the ability to argue “form not covered” at the formulation stage.
Claim 7: What is the therapeutic-use breadth?
Claim 7 is a method-of-treatment claim.
- Target: “cancer in a subject”
- Cancer list (as recited):
- melanoma
- breast cancer
- colorectal cancer
- non-small cell lung cancer
- acute myeloid leukemia
- pancreatic cancer
- Act: administering a therapeutically effective amount of the claimed hemifumarate salt
Practical scope implication
- Claim 7 sets broad therapeutic coverage across multiple indications.
- It is not limited to a biomarker-defined subgroup in the independent claim; that comes in Claim 8 onward.
Claim 8: How is indication scope tightened by biomarker subgroup?
- Claim 8 limits to cancers selected from:
- BRAF V600 mutant melanoma
- triple negative breast cancer
- KRAS mutant colorectal cancer
Practical scope implication
- This claim narrows the method to specific genomic phenotypes.
- It gives additional leverage in litigation because the alleged infringer can be targeted on patient selection if its use aligns to one of these genomic cohorts.
Claim 9: What does the patent do with BRAF V600 mutant melanoma?
- Claim 9: cancer is BRAF V600 mutant melanoma
Practical scope implication
- This makes BRAF V600 melanoma the most litigation-friendly anchor: it is both (i) biomarker-defined and (ii) explicitly carried into the next independent combination claim (Claim 12).
Claims 10–11: Does the method claim split by solid state?
- Claim 10: method where hemifumarate salt is amorphous
- Claim 11: method where hemifumarate salt is crystalline
Practical scope implication
- The patient-treatment method claims are duplicated across amorphous and crystalline embodiments, limiting solid-state defenses.
Claim 12: What is the key combination hook with vemurafenib?
Claim 12 is a combination therapy claim anchored to:
- Condition: BRAF V600 mutant melanoma
- Treatment: administer the hemifumarate salt (as defined) in combination with vemurafenib
Practical scope implication
- This is the most commercially actionable claim because it maps directly onto a common clinical therapeutic partner for BRAF V600 melanoma.
- It adds an enforcement path even if an alleged infringer tries to frame its product as “not used alone” but “used with standard-of-care.”
Claim 13: What timing flexibility is allowed in the combination?
- Claim 13: administration of the hemifumarate salt takes place prior or subsequent to, or concurrent with vemurafenib
Practical scope implication
- Timing-based design-arounds are narrowed.
- If an infringer uses any ordering strategy (sequential or concurrent), the claim language is drafted to capture it.
Claims 14–15: Does the combination claim also lock solid-state?
- Claim 14: hemifumarate salt is amorphous
- Claim 15: hemifumarate salt is crystalline
Practical scope implication
- The combination pathway is reinforced across solid-state variants.
What is the overall scope profile?
1) Product coverage (strongest layer)
- Hemifumarate salt of a single stereochemically defined API: Claim 1
- Solid-state embodiments: Claims 2–3
- Formulation: Claims 4–6
2) Use coverage (indication breadth + biomarker subsets)
- Broad cancer list: Claim 7
- Genomic subsets: Claim 8
- Explicit BRAF V600: Claim 9
3) Combination coverage (highest enforceability in clinic)
- BRAF V600 mutant melanoma + vemurafenib: Claim 12
- No timing escape: Claim 13
- Solid-state embodiments: Claims 14–15
Patent landscape: how this claim strategy positions competitors
Given only the claim text provided, the enforceable landscape can be mapped by how competitors typically develop around salt/form and method claims.
1) Salt-form strategy (most common attempted workaround)
- If a competitor uses the same API but different counterion (not hemifumarate), it may avoid Claim 1 and all salt-specific dependent claims.
- If the competitor uses hemifumarate but changes solid form, it still hits Claims 2 and 3 (and formulation and method dependents).
2) Formulation strategy
- Because Claim 4 is excipient-inclusive and not restricted by dosage form or release characteristics, switching tablet/capsule/film or excipient systems generally does not avoid.
- Solid-state switching alone is covered by Claims 5–6.
3) Indication strategy
- If a competitor targets cancers outside the Claim 7 list, it is outside the therapeutic-use claims as written.
- If it targets within the list, it remains in-bounds unless it avoids the specific biomarker subset captured by Claims 8–9.
4) Combination strategy
- Claim 12 is specifically “in combination with vemurafenib.”
- Claim 13 eliminates timing-based workaround arguments.
- A competitor trying to avoid this claim would generally need to avoid either:
- using vemurafenib, or
- using the claimed hemifumarate salt embodiment for the combination regimen, or
- avoid the BRAF V600 mutant melanoma indication framing.
Enforcement leverage: which claims matter most in practice?
Highest leverage claims
- Claim 1 (hemifumarate salt product scope)
- Claims 2–3 (amorphous/crystalline bifurcation)
- Claim 4 (composition with excipients)
- Claim 12 (BRAF V600 mutant melanoma + vemurafenib combination)
- Claim 13 (no timing escape)
Lower relative leverage (still important)
- Claim 7–11 provide breadth, but in disputes they can become fact-dependent (patient population, dosing, and solid-state form).
- Depending on the litigation posture, independent product claims (1/4) often drive settlement posture more than method proof.
Key Takeaways
- US 11,254,649 is a hemifumarate salt patent with explicit amorphous and crystalline coverage, closing a common solid-state design-around.
- The patent covers both product and pharmaceutical composition layers, with only a minimal formulation requirement (pharmaceutically acceptable excipient).
- Therapeutic-use coverage spans a defined cancer list and is tightened by biomarker subsets, with the strongest clinical hook being BRAF V600 mutant melanoma in combination with vemurafenib.
- The combination timing language in Claim 13 removes a typical workaround based on sequencing versus concurrency.
FAQs
1) Does the patent cover both amorphous and crystalline hemifumarate forms?
Yes. Claims 2 and 3 separately claim amorphous and crystalline hemifumarate salts, and the same split appears in the composition and method dependents (Claims 5–6 and Claims 10–11, 14–15).
2) Is the composition claim limited to a specific dosage form?
No. Claim 4 only requires a pharmaceutical composition comprising the hemifumarate salt plus a pharmaceutically acceptable excipient.
3) Are the therapeutic-use claims limited to biomarker-defined patients?
The broad independent method claim (Claim 7) covers a cancer list without biomarker limitations. Claims 8–9 add biomarker-defined subsets.
4) What makes the vemurafenib combination claim particularly specific?
Claim 12 ties BRAF V600 mutant melanoma directly to administration “in combination with vemurafenib,” and Claim 13 captures prior, subsequent, or concurrent administration.
5) Can timing be used to avoid infringement of the combination claim?
Not based on sequencing, because Claim 13 explicitly covers prior or subsequent or concurrent administration.
References
[1] US Patent 11,254,649. Claims provided in prompt text.
